Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here are three stocks where Wall Street’s estimates seem disconnected from reality and some better opportunities to consider.
Diebold Nixdorf (DBD)
Consensus Price Target: $98.33 (55.7% implied return)
With roots dating back to 1859 and a presence in over 100 countries, Diebold Nixdorf (NYSE:DBD) provides automated self-service technology, software, and services that help banks and retailers digitize their customer transactions.
Why Do We Think DBD Will Underperform?
- Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last five years
- Earnings per share have contracted by 8.4% annually over the last two years, a headwind for returns as stock prices often echo long-term EPS performance
- Low free cash flow margin of -0.7% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
Diebold Nixdorf is trading at $63.15 per share, or 9.6x forward P/E. Dive into our free research report to see why there are better opportunities than DBD.
Assurant (AIZ)
Consensus Price Target: $330 (23.9% implied return)
With roots dating back to 1892 when it was founded by a Civil War veteran, Assurant (NYSE:AIZ) provides specialized insurance products and services that protect major consumer purchases like mobile devices, vehicles, homes, and appliances.
Why Does AIZ Give Us Pause?
- Net premiums earned only expanded by 5.2% annually over the last five years, trailing its insurance peers as its scale limited incremental business
- Earnings growth underperformed the sector average over the last two years as its EPS grew by just 15.6% annually
- Scale is a double-edged sword because it limits the firm’s capital growth potential compared to its smaller competitors, as reflected in its below-average annual book value per share increases of 4.4% for the last five years
Assurant’s stock price of $266.40 implies a valuation ratio of 2x forward P/B. To fully understand why you should be careful with AIZ, check out our full research report (it’s free).
Ocular Therapeutix (OCUL)
Consensus Price Target: $27.09 (265% implied return)
Pioneering a drug delivery platform that can eliminate the need for monthly eye injections, Ocular Therapeutix (NASDAQ:OCUL) develops sustained-release treatments for eye diseases using its proprietary ELUTYX bioresorbable hydrogel technology that gradually releases medication.
Why Do We Steer Clear of OCUL?
- Sales tumbled by 7.7% annually over the last two years, showing market trends are working against it during this cycle
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 7.5% annually while its revenue grew
- Free cash flow margin dropped by 371.3 percentage points over the last five years, implying the company became more capital intensive as competition picked up
At $7.43 per share, Ocular Therapeutix trades at 30.1x forward price-to-sales. If you’re considering OCUL for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.